Kirby McInerney LLP Reminds Hims & Hers Health, Inc. (HIMS) Investors of Class Action Filing and Encourages Investors to Contact the Firm
By:
Kirby McInerney LLP via
Business Wire
July 10, 2025 at 20:00 PM EDT
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) securities during the period of April 29, 2025, through June 23, 2025, inclusive (“the Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [LEARN MORE ABOUT THE CLASS ACTION] On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” under which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy. On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers shares declined $22.25 per share, or approximately 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025. The lawsuit alleges that Hims & Hers failed to disclose to investors that: (1) the Company was engaged in the deceptive promotion and sale of illegitimate, knockoff versions of Wegovy that endangered patients; and (2) as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated. If you purchased or otherwise acquired Hims & Hers securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters without any cost to you. Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. View source version on businesswire.com: https://www.businesswire.com/news/home/20250710800790/en/ Contacts
Kirby McInerney LLP
More NewsView More
3 Stocks Poised to Benefit From Google’s AI Breakthough ↗
December 03, 2025
Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026 ↗
December 03, 2025
3 Stocks You’ll Wish You Bought Before 2026 ↗
December 03, 2025
Via MarketBeat
Wall Street Punished CrowdStrike for Beating Earnings? Seriously? ↗
December 03, 2025
Via MarketBeat
Tickers
CRWD
Okta: Excuses to Sell Vs. Reasons to Buy ↗
December 03, 2025
Via MarketBeat
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|